Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its ...

The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have received a consensus rating of “Moderate Buy” from the seventeen ...

And sometimes you can find stocks that are especially great bargains. Three Motley Fool contributors believe they've done just that. Here's ...

Thanks in part to several acquisitions, Pfizer has multiple new growth drivers in its lineup. They include migraine therapy Nurtec ODT (gained through its 2022 acquisition of Biohaven) and cancer ...

However, the big drugmaker also has multiple strong growth drivers, notably including cancer drugs Adcetris and Padcev and migraine therapy Nurtec ODT. There's another reason to buy Pfizer stock ...